JUPITER (women subgroup) 2008

1 Treatments

**Studied treatment**  Rosuvastatin 20 mg daily

**Control treatment**  placebo

**Concomittant treatments**  -

**initial women proportion in the trial**  6801/17802 (38%)

2 Patients

**Patients**  apparently healthy men and women with low-density lipoprotein cholesterol levels of less than 130 mg/dL and high-sensitivity C-reactive protein levels of 2.0 mg/L or higher - subgroup of women

**Inclusion criteria**  -

**Exclusion criteria**  -

**prior CHD (%)**  0%

**baseline CT**  -

**baseline LDL**  <130 mg/dL

3 Methods

**Blinding**  double-blind

**Design**  Parallel groups

**Centers**  1315

**Geographical area**  26 countries

**Sizes**  3426/3375

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cv events</td>
<td>39/3426</td>
<td>70/3375</td>
<td>0,55</td>
<td>[0,37; 0,81]</td>
</tr>
<tr>
<td>All cause mortality</td>
<td>60/3426</td>
<td>77/3375</td>
<td>0,77</td>
<td>[0,55; 1,08]</td>
</tr>
<tr>
<td>CHD events</td>
<td>0/3426</td>
<td>0/3375</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cancer</td>
<td>0/3426</td>
<td>0/3375</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References